587 related articles for article (PubMed ID: 26791893)
1. Recent advances in the construction of antibody-drug conjugates.
Chudasama V; Maruani A; Caddick S
Nat Chem; 2016 Feb; 8(2):114-9. PubMed ID: 26791893
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
3. [Advances in the study of site-specific antibody-drug conjugates].
Sun Y; Huang R; Sun BW
Yao Xue Xue Bao; 2015 Oct; 50(10):1225-31. PubMed ID: 26837166
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
Singh SK; Luisi DL; Pak RH
Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
[TBL] [Abstract][Full Text] [Related]
5. Methods to Make Homogenous Antibody Drug Conjugates.
Kline T; Steiner AR; Penta K; Sato AK; Hallam TJ; Yin G
Pharm Res; 2015 Nov; 32(11):3480-93. PubMed ID: 25511917
[TBL] [Abstract][Full Text] [Related]
6. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
7. Linker technologies for antibody-drug conjugates.
Nolting B
Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
[TBL] [Abstract][Full Text] [Related]
8. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
9. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
10. Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.
Huang RY; Chen G
Drug Discov Today; 2016 May; 21(5):850-5. PubMed ID: 27080148
[TBL] [Abstract][Full Text] [Related]
11. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
12. Current ADC Linker Chemistry.
Jain N; Smith SW; Ghone S; Tomczuk B
Pharm Res; 2015 Nov; 32(11):3526-40. PubMed ID: 25759187
[TBL] [Abstract][Full Text] [Related]
13. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
[TBL] [Abstract][Full Text] [Related]
14. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
16. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
[TBL] [Abstract][Full Text] [Related]
19. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
20. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.
Harper J; Mao S; Strout P; Kamal A
Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
